NDAORALTABLET, EXTENDED RELEASE1 Generic Approved
Approved
Jan 1959
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MESTINON (pyridostigmine bromide) is an oral acetylcholinesterase inhibitor that increases acetylcholine availability at the neuromuscular junction. It is primarily indicated for myasthenia gravis and related neuromuscular disorders, where it restores muscle strength by enhancing acetylcholine signaling. The extended-release tablet formulation provides sustained drug delivery for chronic disease management.
LOE Approaching
As LOE approaches, brand teams are shifting focus to lifecycle extension strategies, pricing optimization, and transition planning; expect consolidation of commercial support.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Testing Mestinon and Exercise in Fibromyalgia
Started Sep 2002
178 enrolled
Fibromyalgia
Career Relevance
Working on MESTINON offers stability and deep market knowledge in a niche therapeutic area, but limited growth trajectory and declining career momentum as the product approaches LOE. Career advancement requires expertise in portfolio optimization, reimbursement strategy, and lifecycle management rather than launch or expansion leadership.
Brand Manager
Worked on MESTINON at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.